title: Somatostatin in medullary thyroid cancer. In vitro and in vivo studies.
abstract: The authors evaluated the presence of somatostatin (SRIF) in the plasma and in the tumor tissue of a total of 22 patients with medullary thyroid cancer (MTC) and studied the effect of exogenous SRIF administration on basal and pentagastrin (PG)-stimulated plasma calcitonin (CT) and carcinoembryonic antigen (CEA) levels. Mean plasma SRIF concentrations were significantly higher than those found in normal controls, with five of 15 patients having plasma SRIF levels above the mean + 2 SD of normal controls. High immunoreactive SRIF concentrations were found in the extract of three tumor tissues but not in one follicular thyroid cancer or in one toxic diffuse goiter. By immunoperoxidase staining seven of 11 (63.6%) primary MTC and five of 13 (38.5%) metastases expressed SRIF antigen in a low number of cells and with a weak degree of staining. As expected, CT was expressed in almost 100% of the cases with positivity in most of the cells and strong degree of staining. Patients with positive SRIF staining in the primary tumor had longer survival than SRIF negative patients. Infusion of synthetic SRIF (11 micrograms/minute/45 minutes) produced a significant reduction of plasma CT (but not CEA) levels in 12 of the 15 patients submitted to this test. Maximal percent decrease of plasma CT ranged from 10.8% to 72.7% of the basal value and was usually observed between 30 and 45 minutes from the beginning of the infusion. When infused together with the injection of PG, SRIF was able to significantly (P less than 0.05) inhibit the PG-induced CT release in five of six patients tested. These results demonstrate the following: SRIF is present in a few cells of many primary MTC and less frequently in their metastases; tentatively, the expression of SRIF antigen in the tumor seems to be associated with longer survival; increased SRIF concentrations are found in the plasma of some patients with metastatic involvement; and treatment with exogenous SRIF reduces the basal and PG-induced CT (but not CEA) release from the tumor.
authors.affiliation: Cattedra di Endocrinologia, Università di Pisa, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Pacini
authors.forename: R
authors.initials: R
authors.lastname: Elisei
authors.forename: S
authors.initials: S
authors.lastname: Anelli
authors.forename: F
authors.initials: F
authors.lastname: Basolo
authors.forename: A
authors.initials: A
authors.lastname: Cola
authors.forename: A
authors.initials: A
authors.lastname: Pinchera
mesh_terms: D002116:Calcitonin / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002277:Carcinoma / Q000378:metabolism* / Q000556:secondary; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008297:Male; D009377:Multiple Endocrine Neoplasia / Q000378:metabolism; D013004:Somatostatin / Q000378:metabolism* / Q000494:pharmacology; D013964:Thyroid Neoplasms / Q000378:metabolism*
chemical_list: D002272:Carcinoembryonic Antigen; D013004:Somatostatin; D002116:Calcitonin